Orion publishes Interim Report for January–September 2023 on Thursday 26 October 2023
October 16 2023 - 5:15AM
Orion publishes Interim Report for January–September 2023 on
Thursday 26 October 2023
ORION CORPORATION PRESS RELEASE 16 October 2023 at 12.15
EEST
Orion publishes Interim Report for January–September
2023 on Thursday 26 October 2023
Orion will publish Interim Report for January–September 2023 on
Thursday, 26 October 2023 at approximately 12.00 noon EEST. The
report and related presentation material will be available on the
company’s website at www.orion.fi/en/investors after
publishing.
Webcast and conference call
A webcast and a conference call for analysts, investors and
media representatives will be held on Thursday, 26 October 2023 at
13.30 EEST.
A link to the live webcast is available on Orion's website
at www.orion.fi/en/investors. A recording of the event will be
available on the website later the same day.
Confenrence call can be joined by registering through the
following
link:http://palvelu.flik.fi/teleconference/?id=1009428
Phone numbers and the conference ID to access the conference
will be provided after the registration. In case you would like to
ask a question during the conference, please dial *5 on your
telephone keypad to enter the question queue.
Questions can also be presented in writing through the question
form of the webcast.
Silent period
The silent period preceding the publication is ongoing and
continues until the disclosure.
Contact
person:Tuukka Hirvonen, Investor Relations, Orion
Corporationtel. +358 10 426 2721
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandwww.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and self-care products. The core therapy areas of our
pharmaceutical R&D are oncology and pain. Proprietary products
developed by Orion are used to treat cancer, neurological diseases
and respiratory diseases, among others. Orion's net sales in 2022
amounted to EUR 1,341 million and the company had about 3,500
employees at the end of the year. Orion's A and B shares are listed
on Nasdaq Helsinki.
Orion (TG:OFK)
Historical Stock Chart
From May 2024 to Jun 2024
Orion (TG:OFK)
Historical Stock Chart
From Jun 2023 to Jun 2024